Aalborg University Hospital

Running trials

• Not yet recruiting

  BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.

  NCT07474961· Phase 4· Anne Louise Tølbøll Sørensen· Source

• Not yet recruiting

  Dose-Escalated Short-Course Proton Therapy for Locally Advanced Rectal Cancer

  NCT07903883· University of Aarhus· Source

• Recruiting

  The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial

  NCT07442357· Copenhagen University Hospital, Rigshospitalet· Source

• Not yet recruiting

  Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer

  2025-522431-34-00· Phase 2· Region Hovedstaden· Source

• Not yet recruiting

  The OASE study

  2026-525221-21-01· Phase 4· Aalborg University Hospital· Source

• Recruiting

  A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-escalation strategies in patients who respond to treatment.

  NCT01491815· Phase 4· Karolinska Institutet· Source

• Not yet recruiting

  Infarct Growth After Intravenous Tocilizumab in Adults With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy - ILLUMINATE

  NCT07870681· Phase 2/3· Oslo University Hospital· Source

• Not yet recruiting

  bNAbs and Anti-PD-1 in HIV

  NCT07820813· Phase 2· Ole Schmeltz Søgaard· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Incyte Corp.· Source

• Recruiting

  Sublobar Wedge Resection or Stereotactic Radiotherapy Treatment of High-risk Patients With Early-stage Lung Cancer

  NCT07432802· Aarhus University Hospital· Source

• Not yet recruiting

  Rapid or Ultra-rapid Diagnosis of Myocardial Infarction Using High-Sensitivity Cardiac Troponin on Hospital Presentation

  NCT07727135· Herlev and Gentofte Hospital· Source

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· AstraZeneca· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

  NCT07759245· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

  NCT07662135· Phase 3· AstraZeneca· Source

• Not yet recruiting

  Does a higher radiation dose prolong survival of patients with limited-stage small cell lung cancer receiving immunotherapy after chemotherapy and radiation therapy (DAHRTS trial)?

  2026-525513-31-00· Phase 3· Norges Teknisk-Naturvitenskapelige Universitet NTNU· Source

• Recruiting

  Cannabidiol for Pain Relief of Patients With End-stage mCRPC

  NCT07549256· Phase 2· Regionshospital Nordjylland· Source

• Not yet recruiting

  The MAYA2 trial

  2025-521941-25-00· Phase 2· Odense University Hospital· Source

• Recruiting

  Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year

  2025-521590-13-00· Phase 3· Janssen Cilag International· Source

• Recruiting

  A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

  NCT07570173· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

  NCT07549412· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Recruiting

  Prehospital Pulse-dose Glucocorticoid in Patients With ST-segment Elevation Myocardial Infarction 2 - The PULSE-MI 2 Trial

  NCT07478003· Phase 3· Thomas Engstrom· Source

• Not yet recruiting

  A randomized placebo-controlled double-blind trial phase II two-arm study to investigate infarct growth over 72 hours assessed with diffusion weighted imaging on MRI after treatment with intravenous tocilizumab or placebo in patients above 18 years of age with acute ischemic stroke undergoing endovascular thrombectomy.

  2025-521269-28-00· Phase 2· Oslo University Hospital HF· Source

• Recruiting

  Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study)

  NCT07481175· Phase 1· Thomas Aagaard Rasmussen· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( RAINFOL-03 )

  2024-519818-31-01· Phase 3· Genmab A/S· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

  NCT07225270· Phase 3· Genmab· Source

• Recruiting

  LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study

  2025-522338-30-00· Phase 2· Eli Lilly & Co.· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  NCT07067463· Phase 3· Zenas BioPharma (USA), LLC· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

  NCT07299019· Phase 3· Zenas BioPharma (USA), LLC· Source

• Recruiting

  A Randomized, placebo-controlled, double-blinded Phase 2 Trial of Dapagliflozin for Preventing Treatment-associated Cardiotoxicity in Lymphoma

  2025-521205-41-00· Phase 2· Aalborg University Hospital· Source

• Recruiting

  A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  NCT07438496· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Incyte Corporation· Source

• Recruiting

  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  NCT07223814· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Not yet recruiting

  Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer

  NCT07409844· Phase 2· Ismail Gögenur· Source

• Recruiting

  SchoolCare: A Social Intervention Introducing Telepresence Robots and School Navigation to Reduce School Fragmentation for Children Undergoing Cancer Treatment

  NCT07398677· Copenhagen University Hospital, Rigshospitalet· Source

• Recruiting

  A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  NCT07318558· Phase 3· Merck Sharp & Dohme LLC· Source

• Enrolling by invitation

  MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease

  NCT06788340· Phase 4· Odense University Hospital· Source

• Recruiting

  A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

  NCT06980480· Phase 3· Takeda· Source

• Recruiting

  AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

  NCT07218809· Phase 3· AstraZeneca· Source

• Recruiting

  A trial to learn how well AZD0292 works, how safe it is, and how it moves throughout the body over time in people with bronchiectasis and chronic PsA colonization

  2025-523009-14-00· Phase 2· AstraZeneca AB· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Pfizer· Source

• Recruiting

  Automated Insulin Delivery Versus Usual Insulin Treatment Modality Before and During Pregnancy in Women With Type 1 Diabetes

  NCT07240012· Copenhagen University Hospital, Rigshospitalet· Source

• Recruiting

  Improving Treatment for Depression in General Practice Using a Step-by-Step Care Plan.

  NCT07263321· Aalborg University Hospital· Source

• Recruiting

  Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC.

  2024-516906-47-00· Phase 2/3· Daiichi Sankyo Inc.· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

  NCT07166094· Phase 3· Genmab· Source

• Enrolling by invitation

  Optical Coherence Tomography in Acute Vessel Evaluation

  NCT07422688· Aarhus University Hospital Skejby· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

  NCT07059845· Phase 2· AbbVie· Source

• Active, not recruiting

  A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07170150· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

  NCT07186101· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis

  NCT07201051· Phase 2· GlaxoSmithKline· Source

Showing 50 of 274.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers16 recruiting
• Colorectal cancer15 recruiting
• Coronary artery disease9 recruiting
• Atrial fibrillation8 recruiting
• Chronic kidney disease8 recruiting
• Lung cancer8 recruiting
• Acute myeloid leukaemia7 recruiting
• COPD7 recruiting
• Heart failure7 recruiting
• Ovarian cancer7 recruiting
• Stroke7 recruiting
• Bladder cancer5 recruiting
• Chronic lymphocytic leukaemia5 recruiting
• Endometrial cancer5 recruiting
• Pancreatic cancer5 recruiting
• Prostate cancer5 recruiting
• Type 1 diabetes5 recruiting
• Ulcerative colitis5 recruiting
• Acute lymphoblastic leukaemia4 recruiting
• Crohn's disease4 recruiting
• Multiple myeloma4 recruiting
• Osteoporosis4 recruiting
• Bronchiectasis3 recruiting
• Obesity3 recruiting
• Type 2 diabetes3 recruiting
• Alzheimer disease2 recruiting
• ANCA-associated vasculitis2 recruiting
• Aortic stenosis2 recruiting
• Bipolar disorder2 recruiting
• Cerebral palsy2 recruiting
• Depression2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Follicular lymphoma2 recruiting
• Glioblastoma2 recruiting
• High blood pressure2 recruiting
• HIV2 recruiting
• Melanoma2 recruiting
• Metastatic breast cancer2 recruiting
• Migraine2 recruiting
• Multiple sclerosis2 recruiting
• Myelodysplastic syndromes2 recruiting
• Osteoarthritis2 recruiting
• Rheumatoid arthritis2 recruiting
• ALS (motor neurone disease)1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Cystic fibrosis1 recruiting
• Glaucoma1 recruiting
• Head and neck cancer1 recruiting
• Hepatitis B1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Kidney cancer1 recruiting
• Lupus (SLE)1 recruiting
• Lyme disease1 recruiting
• Mantle cell lymphoma1 recruiting
• Mesothelioma1 recruiting
• Peripheral artery disease1 recruiting
• Psoriasis1 recruiting
• Sarcoidosis1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Recruiting

  Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

  NCT07686263· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Active, not recruiting

  A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07169578· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

  NCT06797869· Phase 2· Novo Nordisk A/S· Source

• Terminated

  Comparison of Short Versus 12 Months Prasugrel Plus Aspirin in Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Intervention and Everolimus-eluting Stents

  NCT06718179· Phase 4· Odense University Hospital· Source

• Active, not recruiting

  A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)

  NCT06577935· Phase 2· Angitia Biopharmaceuticals· Source

• Completed

  Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

  NCT06433219· Phase 2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  Intradialytic Kinetics of Cardiac Biomarkers During Hemodialysis and Hemodiafiltration

  NCT06526702· Aalborg University Hospital· Source

• Completed

  A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations

  NCT06529419· Phase 2· AstraZeneca· Source

• Completed

  Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma

  NCT06435273· Phase 2· AstraZeneca· Source

• Active, not recruiting

  Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

  2023-508235-31-00· Phase 3· Almirall S.A.· Source

• Completed

  A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure

  NCT06299826· Phase 2· AstraZeneca· Source

• Active, not recruiting

  A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

  NCT06407934· Phase 3· Sanofi· Source

• Active, not recruiting

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

  NCT06346067· Phase 3· Erasca, Inc.· Source

• Completed

  A Precision Medicine Approach to the Prevention of Depression in Patients With Atrial Fibrillation

  NCT07178691· University of Southern Denmark· Source

• Active, not recruiting

  A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheimer’s Disease (AD)

  2023-506183-13-00· Phase 2· F. Hoffmann-La Roche AG· Source

• Completed

  A Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

  2022-502457-34-00· Phase 2· F. Hoffmann-La Roche AG· Source

• Completed

  An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

  NCT06169397· Phase 2· Xentria, Inc.· Source

• Completed

  A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

  NCT05901831· Phase 3· Bayer· Source

• Completed

  GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer

  2022-502453-33-00· Phase 2· Genmab A/S· Source

• Completed

  A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

  NCT06280391· Phase 2· Sanofi· Source

• Completed

  [68Ga]Ga-FAPI PET/CT in Gastric and Gastroesophageal Junctional Cancer

  NCT05898854· Phase 2· Aalborg University Hospital· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)

  NCT06181435· Phase 3· Sanofi· Source

• Completed

  68Ga-FAPI PET/CT: The Diagnostic Accuracy for Primary Staging and Re-staging of Patients with Ovarian Cancer

  NCT05903807· Phase 2· Aalborg University Hospital· Source

• Completed

  Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

  NCT06020014· Phase 2· AstraZeneca· Source

• Recruiting

  DESTINY Breast Respond HER2-(Ultra)Low Europe

  NCT05945732· Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company· Source

• Terminated

  A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

  NCT06032546· Phase 2· AbbVie· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT06040086· Phase 3· AstraZeneca· Source

• Terminated

  The Innate Immune Response and Enteric Nervous System in Crohn's Disease.

  NCT06485193· Aalborg University Hospital· Source

• Completed

  Comparison of Histamine and Local Heating for Evoking the Axon-reflex Flare Response in Diabetes

  NCT05921097· Aalborg University Hospital· Source

• Completed

  A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT05811351· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

  NCT05742802· Phase 3· AstraZeneca· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Active, not recruiting

  A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

  NCT05469737· Phase 2/3· Bristol-Myers Squibb· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Completed

  Value of Gym-based Exercise Training for Young Adults Receiving Antipsychotic Medication: The Vega Trial

  NCT05461885· Copenhagen University Hospital, Rigshospitalet· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05242484· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Effect of Single vs Multiple Prophylactic Antibiotic Doses on PJI Following Primary THA in Patients With OA

  NCT05530551· Soren Overgaard· Source

• Completed

  Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

  NCT05153239· Phase 3· PharmaMar· Source

• Completed

  Radiation-induced Diarrhoea During Curative EBRT of Prostate and Rectal Cancer

  NCT05684432· Aalborg University Hospital· Source

• Completed

  Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD

  NCT05326412· Phase 2· Sanofi· Source

• Active, not recruiting

  IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

  NCT05155254· Phase 3· IO Biotech· Source

• Completed

  A Study of Population and Sex-specific Troponin Cutoffs for Ruling Out Acute Myocardial Infarction

  NCT05336435· Herlev Hospital· Source

• Completed

  A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study

  2024-511560-93-00· Phase 3· Boehringer Ingelheim International GmbH· Source

• Completed

  En Bloc Transurethral Resection of Non-muscle Invasive Bladder Cancer

  NCT05223491· Jørgen Bjerggaard Jensen· Source

• Completed

  HERES trial: Trastuzumab and standard treatment with chemo- and immunotherapy as first line treatment for HER2 positive esophageal squamous cell carcinoma patients

  NCT05170256· Phase 2· Rigshospitalet· Source

• Active, not recruiting

  Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

  NCT05173987· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

  NCT05186818· Phase 3· Cytokinetics· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease (COPD)

  2023-507093-40-00· Phase 2· Genentech Inc.· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT05166889· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.

  NCT05038735· Phase 3· Novartis Pharmaceuticals· Source

Showing 50 of 105.

Conditions

Diseases this institution publishes on or runs trials for.

• Ulcerative colitis29 works · 11 trials
• Type 1 diabetes21 works · 7 trials
• Aortic stenosis17 works · 4 trials
• Macular degeneration12 works · 1 trial
• Diffuse large B-cell lymphoma9 works · 6 trials
• Hypothyroidism8 works · 0 trials
• Graves' disease and hyperthyroidism7 works · 0 trials
• Fibromyalgia5 works · 0 trials
• Mesothelioma5 works · 3 trials
• Mantle cell lymphoma4 works · 4 trials